Skip to main content
SpringerLink
Log in
Book cover

Combined Modality Therapy of Gastrointestinal Tract Cancer pp 198–206Cite as

Phase-II-Study with EAP (Etoposide, Adriamycin, Cis- Platinum) in Patients with Primary Inoperable Gastric Cancer and Advanced Disease

  • Conference paper

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 110))

Abstract

In the past approximately 35% of patients with advanced gastric cancer (AJC stage 4) survived 1 year after surgery and only 4% lived 4 years [1]. Most patients died because of local recurrence and/or metastases [2]. Today, advanced gastric cancer seems to respond partly to chemotherapy. Active chemotherapy combinations achieve better results than single-agent chemotherapy [3–7]. A remission rate of approximately 20% can be achieved with 5-fluorouracil [4, 5, 8–10], adriamycin [9, 11,12], etoposide [13], BCNU [9,14], and mitomycin C [15,16].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Curtis RE, Kennedy BJ, Myers MH, Hankey BF (1985) Evaluation of AJC stomach cancer staging using the seer population. Semin Oncol 12: 21–31

    PubMed  CAS  Google Scholar 

  2. Comis RL (1982) The therapy of stomach cancer. In: Carter SK, Glatstein E, Livingston RB (eds) Principles of cancer treatment. McGraw-Hill, New York, p 420

    Google Scholar 

  3. Lacave AJ, Wils J, Diaz-Rubio E, Clavel M, Planting A, Bleiberg H, Duez N, Dalesio O (1985) Phase-II study of cisplatin (cDDP) in chemotherapy-resistant carcinoma of the stomach. Cancer Chemother Pharmacol 14 [Suppl]: 39

    Google Scholar 

  4. Cocconi G, DeLisi V, DiBlasio B (1982) Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66: 1263–1266

    PubMed  CAS  Google Scholar 

  5. Kolaric K, Potrebica V, Stanovnik M (1986) Controlled phase-III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus S-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 43: 73–77

    Article  PubMed  CAS  Google Scholar 

  6. Moertel CG, Mittelman JA, Bakermeier, RF, Engstrom P, Hanely J (1976) Sequential and combination chemotherapy of advanced gastric cancer. Cancer 38: 678

    Article  PubMed  CAS  Google Scholar 

  7. Wagener DJTh, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoog-endoorn GJ, Scheerder H, van der Vegt SGL (1985) Phase-II trial of 5-fluorouracil, adri-amycin and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15:86–87

    Article  PubMed  CAS  Google Scholar 

  8. Bullen BR, Giles GR, Malhotra A, Bird GG, Hall R, Bunch GA, Brown GJA (1976) Randomized comparison of melphalan and 5-fluorouracil in the treatment of advanced gastrointestinal cancer. Cancer Treat Rep 60: 1267–1271

    PubMed  CAS  Google Scholar 

  9. MacDonald JS, Gunderson LL, Cohn I Jr (1982) Cancer of the stomach. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer — principles and practice of oncology. Lippin-cott, Philadelphia, p 534

    Google Scholar 

  10. De Lisi V, Cocconi G, Tonato M, Di Costanzo F, Leonardi F, Soldani M (1986) Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase-III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treat Rep 70: 481–485

    PubMed  Google Scholar 

  11. Moertel CG, Lavin PT (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863–1869

    PubMed  CAS  Google Scholar 

  12. The Gastrointestinal Tumor Study Group (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1871–1876

    Google Scholar 

  13. Kelsen DP, Magill G, Cheng E, Coonley C, Yagoda A (1982) Phase-II trial of etoposide (VP16) in the treatment of upper gastrointestinal malignancies. Proc American Society of Clinical Oncology 1, p 96, (Abstract) C-371

    Google Scholar 

  14. Moertel CG (1973) Therapy of advanced gastrointestinal cancer with the nitrosoureas. Cancer Chemother Rep 4: 27–34

    CAS  Google Scholar 

  15. Comis RL (1979) Mitomycin C in gastric cancer. In: Carter SK, Crooke ST (eds) Mitomycin C — current status and new developments. Academic, New York, p 129

    Google Scholar 

  16. Schein PS, Macdonald JS, Hoth D, Wooley PV (1978) Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol 1: 73–75

    Article  PubMed  CAS  Google Scholar 

  17. Kantarjian H, Ajani JA, Karlin DA (1985) cis-Diamminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 42: 69–71

    Article  PubMed  CAS  Google Scholar 

  18. Beer M, Cocconi G, Ceci G, Varini M, Cavalli F (1983) A phase-II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19: 717–720

    Article  PubMed  CAS  Google Scholar 

  19. Aabo K, Pedersen H, Rørth M (1985) Cisplatin in the treatment of advanced gastric carcinoma: a phase-II study. Cancer Treat Rep 69: 449–450

    PubMed  CAS  Google Scholar 

  20. Leichman L, MacDonald B, Dindogru A, Samson M (1982) Platinum: a clinically active drug in advanced adenocarcinoma of the stomach. Proc Am Ass Cancer Res 110, Abstract 430

    Google Scholar 

  21. Aisner J, van Echo DA, Whitacre M, Wiernik PH (1982) A phase-I trial of continuous-infusion VP-16-213 (Etoposide). Cancer Chemother Pharmacol 7: 157–160

    PubMed  CAS  Google Scholar 

  22. Greco FA, Johnson DH, Hande RK, Porter LL, Hainsworth JD, Wolff SN (1985) High-dose etoposide (VP-16) in small-cell lung cancer. Semin Oncol 12 (Suppl 2): 42–44

    PubMed  CAS  Google Scholar 

  23. Achterrath W, Niederle N, Hilgard P (1982) Etoposide — chemistry, preclinical and clinical pharmacology. Cancer Treat Rev9 (Suppl A): 3–13

    Article  PubMed  Google Scholar 

  24. Rose WC, Bradner WT (1984) In vivo experimental antitumor activity of etoposide. In: Issell BF, Muggia FM, Carter SK (eds) Etoposide (VP-16) — current status and new developments. Academic, New York, p 33

    Google Scholar 

  25. Mabel JA, Little AD (1979) Therapeutic synergism in murine tumors for combinations of cis-dichlorodiammineplatinum with VP-16-213 or BCNU. Proc Am Ass Cancer Res & Am Soc Clin Oncol no 20, p 230, Abstract 929

    Google Scholar 

  26. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP (1979) cis-Diamminedi-chloroplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 63: 1459–1473

    PubMed  CAS  Google Scholar 

  27. Soloway MS, Masters SB, Murphy WM (1980) Cisplatin analogs and combination chemotherapy in the therapy of murine bladder cancer. In: Prestyako A, Crooke ST, Carter S (eds) Cisplatin — current status and new developments. Academic, New York, p 345

    Google Scholar 

  28. Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 2: 50–65

    Google Scholar 

  29. Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 42: 905–922

    Google Scholar 

  30. Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST (1982) In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum (II). Cancer Res 67: 4719–4725

    Google Scholar 

  31. Seeber S (1982) Model studies of etoposide resistance. Cancer Treat Rep 9 [Suppl A]: 15–20

    Article  Google Scholar 

  32. Gandara D, Wold H, DeGregorio M, Lawrence HJ, Köhler M, George C (1986) High-dose cisplatin (200 mg/m2) in non-small-cell lung cancer (NSCLC): reduced toxicity of a modified dose schedule. Proc American Society of Clinical Oncology, no 5, p 173

    Google Scholar 

  33. Panettiere FJ, Lehane D, Fletcher WS, Stephens R, Rivkin S, McCracken JD (1980) cis-Platinum therapy of previously treated head and neck cancer: the Southwest Oncology Group’s two-dose-per-month outpatient regimen. Med Pediatr Oncol 8: 221–225

    Article  PubMed  CAS  Google Scholar 

  34. Creech RH, Catalano RB, Shah MK (1980) An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients. Cancer 46: 433–437

    Article  PubMed  CAS  Google Scholar 

  35. Wilke H, Achterrath W, Gunzer U, Preusser P (in press) Etoposide and split-dose cisplatin (CCDP) in small-cell lung cancer (SCLC) — improved results

    Google Scholar 

  36. Preusser P, Wilke H, Neuhaus B, Achterrath W (1986) Pilotstudie mit der Kombination Etoposid, Adriamycin, Cisplatin beim fortgeschrittenen Magenkarzinom. Tumor Diagnostik und Therapie 7: 142–144

    Google Scholar 

  37. Wiltshaw E (1983) Chemotherapy of ovarian malignancies at the Royal Marsden Hospital. In: Bender HG, Beck L (eds) Carcinoma of the ovary. Fischer, Stuttgart, p 169

    Google Scholar 

  38. O’Connell MJ (1985) Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 3: 1032–1039

    PubMed  Google Scholar 

  39. The Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17

    Article  Google Scholar 

  40. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR (1984) An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2: 1372–1381

    PubMed  Google Scholar 

  41. MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C (1980) 5-Fluorouracil, doxorubicin, and mito-mycin (FAM) combination — chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536

    PubMed  CAS  Google Scholar 

  42. Beretta G, Fraschini P, Labianca R, Luporini G (1982) The value of FAM polychemo-therapy in advanced gastric carcinoma. Proc American Society of Clinical Oncology 23, p 103, Abstract C-400

    Google Scholar 

  43. Panettiere FJ, Haas Ch, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N, Heil-brun LK, Chen TT (1984) Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. J Clin Oncol 2: 420–424

    PubMed  CAS  Google Scholar 

  44. Oshima K, Yamada T, Nonaka T, Aoyama M, Hirose H, Adachi N, Kobayachi S, Udo K (1982) Treatment of advanced G. I. cancer patients with 5-FU, adriamycin, and mitomycin C (FAM). Proc 13th Intern Cancer Congress, Seattle, September 8–15, no 665 (Abstract 3977)

    Google Scholar 

  45. Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol 8: 277–280

    Article  PubMed  CAS  Google Scholar 

  46. Beretta G, Fraschini P, Labianca R, Arnoldi E, Pancera G, Tedeschi M, Tedeschi L, Luporini G (1986) Weekly 5-fluorouracil (F) versus combination chemotherapies for advanced gastrointestinal carcinomas. A prospective study program. Proc American Society of Clinical Oncology 5, p 94, Abstract 367

    Google Scholar 

  47. Haas C, Oishi N, McDonald B, Coltman C, O’Bryan R (1983) Southwest Oncology Group phase II-III gastric cancer study: 5-fluorouracil, adriamycin, and mitomycin-C +vincristine (FAM vs V-FAM) compared to chlorozotocin (CZT), M-AMSA, and di-hydroxyanthracenedione (DHAD) with unimpressive differences. Proc American Society of Clinical Oncology, no 2, p 122, Abstr C-478

    Google Scholar 

  48. Klein HO, Wickramanayake PD, Farrokh G-R (1986) 5-Fluorouracil (5-FU), adriamycin (ADM), and methotrexate (MTX) — a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc American Society of Clinical Oncology, no 5, p 84, Abstract 325

    Google Scholar 

  49. Wils J, Bleiberg H, Blijham G, Breed W, Diaz-Rubio E, Mulder N, Neijt J, Planting A. Splinter T, van Toorn W, Duez N, Dalesio O (1986) An EORTC Gastrointestinal (GI) Group phase-II evaluation of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) combined with adriamycin (A) (FAMTX) in advanced gastric cancer. Proc American Society of Clinical Oncology, no 78, Abstract 302

    Google Scholar 

  50. Cunningham D, Gilchrist NL, Forrest GJ, Soukop M, McArdle CS, Carter DC (1985) Chemotherapy in advanced gastric cancer. Cancer Treat Rep 69: 927–928

    PubMed  CAS  Google Scholar 

  51. Herrmann R, Heim M, Ho AD, Fritze D, Queißer W, Schlag P (1984) Methotrexate (M), 5-fluorouracil (F) and adriamycin (A) in metastatic or locally advanced gastric cancer. J Cancer Res Clin Oncol 107 [Suppl]: 53

    Article  Google Scholar 

  52. Scherdin G, Garbrecht M, Müllerleile U, Hossfeld DK (1986) Polychemotherapy with methotrexate in medium dosage range, 5-fluorouracil and adriamycin in advanced gastric carcinoma. J Cancer Res Clin Oncol 111 [Suppl]: 85

    Article  Google Scholar 

  53. Rougier P, Droz JP, Amiel JL, Ruffier P, Theodore C, Kac J, Chavy A (1985) Gastric carcinoma: a phase-II trial of chemotherapy with association 5-fluorouracil (5-FU), adriamycin (ADR) and cis-platinum (cDDP) (FAP protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 14 [Suppl]: 54

    Google Scholar 

  54. Moertel C, Fleming T, O’Connell M, Schutt A, Rubin J (1984) A phase-II trial of combined intensive course 5-FU, adriamycin and cis-platinum in advanced gastric and pancreatic carcinoma. Proc American Society of Clinical Oncology, no 137, Abstract 533–535

    Google Scholar 

  55. Figoli F, Galligioni E, Crivellari D, Vaccher E, Lo Re G, Tumolo S, Veronesi A, Frustaci S, Canale V, Monfardini S (1986) Cisplatin (DDP) in combination with adriamycin (A) and fluorouracil (F) (DAF) in advanced gastric cancer — a phase-II study. Proc American Society of Clinical Oncology, no 95, (Abstract 369)

    Google Scholar 

  56. Wooley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C, Lagarde C, Schein P (1981) A phase-II trial of 5-FU, adriamycin and cisplatin (FAP) in advanced gastric cancer. Proc American Association for Cancer Research and of the American Society of Clinical Oncology, no 22, p 455, Abstract C-481

    Google Scholar 

  57. Schnitzler G, Queißer W, Heim ME, König H, Katz R, Fritze D, Herrmann R, Arnold H, Henss H, Trux FA, Bloch R, Keymling M, Wolkewitz KD, Fritsch H, Hanisch I, Brumen L, Edler L (1986) Phase-III study of 5-FU and carmustine versus 5-FU, carmus-tine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep 70: 477–479

    PubMed  CAS  Google Scholar 

  58. Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Br Med J 2: 1471–1473

    Article  PubMed  CAS  Google Scholar 

  59. Queißer W, Flechtner H, Heim ME, Henß H, Arnold H, Fritze D, Herrmann R, Fritsch H, Penzkofer F, Trux FA, Kabelitz K, Edler L (1986) 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) for advanced gastric carcinoma. A phase-II trial. J Cancer Res Clin Oncol 111 [Suppl]: 85

    Google Scholar 

  60. Miller AB, Hoogstraaten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207–214

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chirurgische Klinik und Poliklinik, Westfälische Wilhelms-Universität, Jungeboldtplatz 1, 4400, Münster, Germany

    P. Preusser, H. Wilke, W. Achterrath, U. Fink, P. Neuhaus, J. Meyer, H.-J. Meyer & J. van de Loo

Authors
  1. P. Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Achterrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Neuhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H.-J. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. van de Loo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Chirurgische Klinik, Klinikum der Universität Heidelberg, Im Neuenheimer Feld 110, 6900, Heidelberg, Germany

    Peter Schlag  & Peter Hohenberger  & 

  2. Departement Chirurgie, Universitätsspital Zürich, Rämistraße 100, 8091, Zürich, Switzerland

    Urs Metzger

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Preusser, P. et al. (1988). Phase-II-Study with EAP (Etoposide, Adriamycin, Cis- Platinum) in Patients with Primary Inoperable Gastric Cancer and Advanced Disease. In: Schlag, P., Hohenberger, P., Metzger, U. (eds) Combined Modality Therapy of Gastrointestinal Tract Cancer. Recent Results in Cancer Research, vol 110. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83293-2_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83293-2_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-83295-6

  • Online ISBN: 978-3-642-83293-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation